4//SEC Filing
Morl Christopher John 4
Accession 0001209191-20-001759
CIK 0001654151other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:15 PM ET
Size
19.5 KB
Accession
0001209191-20-001759
Insider Transaction Report
Form 4
Morl Christopher John
Chief Business Officer
Transactions
- Sale
Common Stock
2020-01-02$58.38/sh−3,529$206,039→ 4,103 total - Sale
Common Stock
2020-01-02$59.48/sh−2,103$125,087→ 2,000 total - Sale
Common Stock
2020-01-02$61.58/sh−800$49,266→ 400 total - Sale
Common Stock
2020-01-02$62.25/sh−400$24,900→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-02−16,137→ 179,309 totalExercise: $3.95Exp: 2026-10-20→ Common Stock (16,137 underlying) - Exercise/Conversion
Common Stock
2020-01-02$3.95/sh+16,137$63,741→ 16,137 total - Sale
Common Stock
2020-01-02$57.74/sh−8,505$491,117→ 7,632 total - Sale
Common Stock
2020-01-02$60.58/sh−800$48,463→ 1,200 total
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.11 to $58.10, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.14 to $58.87, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.16 to $60.12, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.24 to $60.76, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.25 to $61.72, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F7]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of October 3, 2016, subject to continued service through such dates.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001716821
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:15 PM ET
- Size
- 19.5 KB